Hosted on MSN6d
Piper Sandler Initiates Coverage of Bright Minds Biosciences (DRUG) with Overweight RecommendationFintel reports that on January 23, 2025, Piper Sandler initiated coverage of Bright Minds Biosciences (NasdaqCM:DRUG) with a ...
Bright Minds Biosciences Inc. (NASDAQ:DRUG) has been able to initiate its phase 2 BREAKTHROUGH study using its 5-HT2C agonist BMB-101 for the treatment of adult patients with classic Absence ...
Dr. Collins brings extensive drug development and clinical expertise in epilepsy -- NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ...
Hosted on MSN22d
Bright Minds Biosciences Appoints New Chief Medical Officer to Advance CNS TherapeuticsDiscover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener An announcement ...
Bright Minds Biosciences stock opened at $38.89 on Friday. The stock has a market cap of $172.44 million, a price-to-earnings ratio of -57.19 and a beta of -6.52. Bright Minds Biosciences has a 1 ...
Piper Sandler initiated coverage of Bright Minds Biosciences (DRUG) with an Overweight rating and $93 price target The firm believes the ...
Analysts at Cantor Fitzgerald initiated coverage on shares of Bright Minds Biosciences (NASDAQ:DRUG – Get Free Report) in a note issued to investors on Friday, MarketBeat.com reports.
Bright Minds Biosciences (DRUG) is finishing 2024 as one of the best-performing small-cap stocks, posting a remarkable 2400% increase in the share price in the last quarter. News of the firm’s ...
NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback